one large placebo controlled RCT of 3002 participants
who received fondaparinux and demonstrated a signiÔ¨Åcant reduction in symptomatic VTE, SVT extension, and
SVT recurrence in comparison with placebo. Major

Journal of Vascular Surgery: Venous and Lymphatic Disorders

Gloviczki et al

55

Volume 12, Number 1

bleeding was infrequent in both groups. A second systematic review and meta-analysis